Evidence map›Paper›PMID 41671421›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Redefining Dendritic Cell Vaccines: Synergistically Co-priming DC and B Cells With Nanoparticles Loading Whole Cell Antigens Maximizes the Efficacy of DC Vaccines.

Xiangxiang Xu, Xianlan Chen, Jin Wang, Yuhan Liu, Sidra Mustafa, Lu Diao, Rongrong Zhao, Haiyang Chi, Kang Hu, Jiashan Zhu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiangxiang XuDepartment of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou, P. R. China.
Xianlan ChenDepartment of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou, P. R. China.
Jin WangDepartment of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou, P. R. China.
Yuhan LiuDepartment of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou, P. R. China.
Sidra MustafaDepartment of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou, P. R. China.
Lu DiaoDepartment of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou, P. R. China.
Rongrong ZhaoDepartment of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou, P. R. China.
Haiyang ChiDepartment of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou, P. R. China.
Kang HuInstitute of Minimally Invasive Thoracic Cancer Therapy and Translational Research, Soochow University, Suzhou, Jiangsu, P. R. China.
Jiashan ZhuInstitute of Minimally Invasive Thoracic Cancer Therapy and Translational Research, Soochow University, Suzhou, Jiangsu, P. R. China.
Jun ZhaoInstitute of Minimally Invasive Thoracic Cancer Therapy and Translational Research, Soochow University, Suzhou, Jiangsu, P. R. China.
Mi LiuDepartment of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou, P. R. China.ORCID https://orcid.org/0000-0002-5185-5872

Funding

China, and Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou 215123People's Republic of China and Wuxi Boston Biopharmaceutical Co., Ltd., Wuxi 214125Suzhou Ersheng Biopharmaceutical Co., Ltd., Suzhou 215123
6 · The paper itself

Abstract

Dendritic cells (DC) play core roles in inducing antigen-specific T cells. However, limited effectiveness hinders their applications as vaccines. To improve the efficacy of traditional DC vaccines, this study optimized three aspects: tumor antigens, cell sources and co-incubating molecules, and thus proposed a new DC-BC vaccine: co-priming B cells and DC at a precise ratio. The therapeutic efficacy was significantly improved by co-incubating DC and B cells. Regarding tumor antigens, utilizing nanoparticles loading whole-tumor lysates performed better than utilizing nanoparticles loading multiple neo-antigens, or nanoparticles loading only water-soluble lysates, or free whole-tumor lysates. Moreover, adding IL-15 and αPD-L1 antibody further bettered DC-BC vaccines. The optimal DC-BC vaccines showed excellent therapeutic efficacy with a 100% response rate and could cure most tumor-bearing mice on several different cancer models, including melanoma, lung cancer and orthotopic pancreatic cancer. The mechanism investigation demonstrated that several molecules, including Ticam1 (TRIF), Traf3, Mavs, and Ifnar2, were involved in promoting APC maturation and improving therapeutic efficacy of vaccines by activating innate immune pathways (TLR/NLR/RLR). In summary, this study provides a new DC-BC vaccine that has much better therapeutic efficacy and explores the underlying mechanism of why co-incubating DC and B cells improved the therapeutic efficacy.

Indexed as

Antigens, NeoplasmB-LymphocytesCancer VaccinesDendritic CellsNanoparticlesAnimalsFemaleMiceMice, Inbred C57BLAntigens, NeoplasmCancer VaccinesB cellcancer immunotherapycancer vaccineDC‐BC vaccinedendritic cell

Identifiers

PMID41671421
PMCPMC13088298

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.